I have just had my fourth Zoladex implant and this is a summary my progress since I posted my profile.
After three months my PSA had dropped to 0.5 from its previous 1.0. I was having occasional blood in my urine but was told this should settle down.
At six months my PSA was 0.4. I had begun to experience pain in my left hip and my right ankle was very sensitive to warm (in the shower) water. I was still having blood in my urine. I was told that things were "still holding on".
At seven months I have a stumble and jarred my left hip which caused me extreme pain. I was taken to the ER given morphine and x-rayed . There was no break but a bone scan was advised.
The bone scan showed that the metastases had grown. My GP referred me to a Radiation Oncologist. I was given five treatments of IMBR and I am now free of pain in my hip and can shower without wincing. It is a pity that they and fix fatigue as easily.
Last week my PSA was reviewed. It was back at 1.0 and I was told that Zoledex had failed. I would now have Casodex added to Zoladex my PSA checked in two months. I asked about Zytega ot Xtandi but was lold that there required special approval on the Australian Pharmaceutical Benefits Scheme as they Chemotherapy. I didn't think they were. I will wait to see how things progress and see my my Medical Oncologist who had advised me previously.
I now will have two month wait to see how I get on. At least Louis still gets his walks down by the creak .
Brian
This these are PBS requirement to receive Zytiga for $39.00 instead of $3,900.00
Castration resistant metastatic carcinoma of the prostate
Clinical criteria:
The treatment must be used in combination with a corticosteroid,
AND
The treatment must not be used in combination with chemotherapy,
AND
Patient must have failed treatment with docetaxel due to resistance or intolerance; OR
Patient must be unsuitable for docetaxel treatment on the basis of predicted intolerance to docetaxel,
AND
Patient must have a WHO performance status of 2 or less,
AND
Patient must not receive PBS-subsidised abiraterone if progressive disease develops while on abiraterone,
AND
Patient must not have received prior treatment with enzalutamide; OR
Patient must have developed intolerance to enzalutamide of a severity necessitating permanent treatment withdrawal.